Jimandin

Sitagliptin, the active ingredient in Jimandin, is a DPP‑4 inhibitor presented as an oral tablet for oral use. It is employed to improve glycemic control in adults with type 2 diabetes mellitus by enhancing the incretin system and supporting glucose‑dependent insulin secretion.\n\nGNH India supplies Jimandin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, ensuring reliable access to quality medicines across multiple regions.

Sitagliptin is a DPP‑4 inhibitor used to manage hyperglycaemia in the type 2 diabetes therapeutic area.\n\nType 2 diabetes mellitus: improves glycaemic control when combined with diet and exercise.\nCombination therapy with metformin: provides additional HbA1c reduction in patients inadequately controlled on metformin alone.\nMonotherapy: offers an oral option for patients who cannot tolerate other antihyperglycaemic agents.

Sitagliptin may cause a range of adverse reactions, most of which are mild and reversible.\n\nCommon Side Effects:\n- Nasopharyngitis: mild upper respiratory symptoms such as sore throat or runny nose.\n- Headache: transient mild to moderate head pain.\n- Upper respiratory tract infection: cough, congestion, or sinus discomfort.\n- Gastrointestinal upset: nausea, abdominal pain, or diarrhoea.\n- Dizziness: occasional light‑headed sensation.\n\nSerious or Rare Side Effects:\n- Pancreatitis: severe abdominal pain that may radiate to the back, requiring immediate medical attention.\n- Severe allergic reactions: rash, angio‑edema, or anaphylaxis.\n- Joint pain: unexplained arthralgia that can be disabling.\n- Hepatic injury: elevated liver enzymes or hepatitis.\n- Hypersensitivity reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating sitagliptin therapy, clinicians should consider several safety factors.\n\nRenal function monitoring: assess creatinine clearance and adjust therapy as needed.\nHistory of pancreatitis: avoid use in patients with prior acute pancreatitis.\nHypersensitivity assessment: discontinue if signs of allergic reaction appear.\nHepatic function evaluation: monitor liver enzymes in patients with liver disease.\nDrug‑specific warnings: be aware of potential for severe joint pain.\nStore at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Sitagliptin can interact with other medicines, altering its efficacy or safety profile.\n\nMajor Interactions (Avoid):\n- Insulin: may increase risk of hypoglycaemia when used together.\n- Sulfonylureas: combined use can potentiate hypoglycaemic events.\n- Strong CYP3A4 inducers (e.g., rifampin): can markedly reduce sitagliptin exposure.\n\nModerate Interactions (Monitor Closely):\n- Digoxin: sitagliptin may raise digoxin concentrations.\n- Diuretics: may affect glucose control and electrolyte balance.\n- ACE inhibitors: concurrent use may enhance antihypertensive effects.